Render Target: STATIC
Render Timestamp: 2025-02-14T10:46:50.466Z
Commit: 7500bcdc731e9059bbdfbdbe9e72caa896e426e8
XML generation date: 2024-04-30 22:03:43.177
Product last modified at: 2025-01-01T09:06:50.278Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Antibody Sampler Kit
PDP - Template ID: *******4a3ef3a

NSD Family Antibody Sampler Kit #16144

    Product Information

    Product Description

    The NSD Family Antibody Sampler Kit provides an economical means of detecting NSD protein family members. The kit includes enough antibodies to perform two western blot experiments with each primary antibody.

    Background

    The nuclear receptor SET domain-containing (NSD) family of histone H3 lysine 36 (H3K36) methyltransferases contains the NSD1, WHSC1/NSD2, and WHSC1L1/NSD3 proteins. More specifically, these enzymes catalyze mono- and di-methylation of H3K36, marks that are typically associated with transcriptionally active regions of the genome (1,2). NSD1 is required for proper embryonic development (3), and mutations in NSD1 are believed to be major contributing factors to the overgrowth disorder, Sotos syndrome (4-6). NSD1 is also mutated or has altered expression in several types of cancer and is thought to exert tumor suppressive or promoting functions depending on cellular context (7-11). WHSC1/NSD2 haploinsufficiency is implicated in the developmental disorder, Wolf-Hirschhorn syndrome, which is characterized by delayed growth, mental retardation, and congenital heart defects (12). In addition, WHSC1 is overexpressed and associated with poor prognosis in a large variety of human cancers, including neuroblastoma and ovarian, hepatocellular, endometrial, and colorectal carcinoma (13-17).  WHSC1L1/NSD3 can function as an oncogene or a tumor suppressor protein and has been shown to regulate expression of several genes associated with cell cycle (18). Amplification and/or increased expression of WHSC1L1/NSD3 in breast, lung, and liver cancer increases growth and survival, and is associated with poor prognosis (18-21).
    1. Wagner, E.J. and Carpenter, P.B. (2012) Nat Rev Mol Cell Biol 13, 115-26.
    2. Bennett, R.L. et al. (2017) Cold Spring Harb Perspect Med 7, a026708. doi: 10.1101/cshperspect.a026708.
    3. Rayasam, G.V. et al. (2003) EMBO J 22, 3153-63.
    4. Kurotaki, N. et al. (2002) Nat Genet 30, 365-6.
    5. Douglas, J. et al. (2003) Am J Hum Genet 72, 132-43.
    6. Rio, M. et al. (2003) J Med Genet 40, 436-40.
    7. Bianco-Miotto, T. et al. (2010) Cancer Epidemiol Biomarkers Prev 19, 2611-22.
    8. Zhang, S. et al. (2019) J Exp Clin Cancer Res 38, 467.
    9. Cancer Genome Atlas Network collaborators (2015) Nature 517, 576-82.
    10. Berdasco, M. et al. (2009) Proc Natl Acad Sci USA 106, 21830-5.
    11. Krossa, I. et al. (2022) Cancers (Basel) 14, 4865. doi: 10.3390/cancers14194865.
    12. Stec, I. et al. (1998) Hum Mol Genet 7, 1071-82.
    13. Hudlebusch, H.R. et al. (2011) Clin Cancer Res 17, 2919-33.
    14. Yang, S. et al. (2013) Biomarkers 18, 257-63.
    15. Zhou, P. et al. (2013) Pathol Oncol Res 19, 303-9.
    16. Xiao, M. et al. (2013) J Surg Oncol 107, 428-32.
    17. Hudlebusch, H.R. et al. (2011) Cancer Res 71, 4226-35.
    18. Zhou, Z. et al. (2010) Biochem Biophys Res Commun 398, 565-70.
    19. Angrand, P.O. et al. (2001) Genomics 74, 79-88.
    20. Yang, Z.Q. et al. (2010) Cancer Res 70, 8487-97.
    21. Kang, D. et al. (2013) Genes Chromosomes Cancer 52, 126-39.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.